dansyl-L-cysteine | 52717-48-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: dansyl-L-cysteine
• 英文别名: N-(5-dimethylaminonaphthalene-1-sulfonyl)-cysteine；(2R)-2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-3-sulfanylpropanoic acid
• CAS: 52717-48-3
• 化学式: C₁₅H₁₈N₂O₄S₂
• 分子量: 354.451
• InChiKey: KXNJZQMDSRVUDK-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  96.1
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  、 Dan-Cys(1)-OH.Dan-Cys(1)-OH 、 二甲基亚砜 、 2-吗啉乙磺酸 、 、 、 水 、 在 amino-microparticles 作用下， 以 1,4-dithio-D,L-threitol 为溶剂， 反应 5.0h， 生成 dansyl-L-cysteine
  参考文献：
  名称：

  Covalent attachment of specific binding members to a solid phase with

  摘要：

  一种特定的结合成员，如抗原或抗体，通过共价结合到固相上，如乳胶微粒。固相与杂二功能或同二功能偶联剂反应形成复合物，然后与二硫化合物反应形成硫化固相。特定的结合成员与偶联剂反应形成复合物，然后与硫化固相反应，通过硫醚键将特定的结合成员与固相链接。或者，二硫化合物可以与特定的结合成员/偶联剂复合物反应形成硫化复合物，然后与固相/偶联剂复合物反应。偶联剂可以包含一个间隔物。在另一种实施方式中，固相与二硫化合物反应形成复合物，然后与还原剂反应形成硫化固相，然后与特定的结合成员/偶联剂复合物反应。固定的特定结合成员可以用于诊断结合分析中，具有增加的灵敏度，特异性和稳定性，同时需要使用更少的特定结合成员。

  公开号：

  US05399501A1

文献信息

• Methods and Compounds for Detection of Medical Disorders
  申请人：Ziv Ilan

  公开号：US20070232702A1

  公开（公告）日：2007-10-04

  The invention provides methods for detection of medical disorders, associated with cellular oxidative stress, cell degeneration and/or cell death. The invention further relates to compounds comprising a thiol (—SH) group, for detecting cells undergoing oxidative stress, degeneration and/or a death process. The invention further provides methods for utilizing the compounds in medical practice, for diagnostic and therapeutic purposes.

  这项发明提供了检测与细胞氧化应激、细胞退化和/或细胞死亡相关的医学疾病的方法。该发明还涉及包含硫醇（—SH）基团的化合物，用于检测正在经历氧化应激、退化和/或死亡过程的细胞。该发明还提供了利用这些化合物进行医学实践的方法，用于诊断和治疗目的。
• Surface modification for improving biocompatibility
  申请人：The Children's Hospital of Philadelphia

  公开号：US20030044408A1

  公开（公告）日：2003-03-06

  A therapeutic delivery system efficiently introduces biologically active molecules to mammalian cells without the use of synthetic polymers or biopolymer coatings. Surface modification of a metal support, such as a medical device, results in a single molecular layer that can fasten various molecules, thereby minimizing any cellular inflammatory response while enhancing biocompatibility.

  一种治疗性输送系统能够高效地将生物活性分子引入哺乳动物细胞，而无需使用合成聚合物或生物聚合物涂层。对金属支撑物进行表面改性，如医疗器械，形成一个单分子层，可固定各种分子，从而最大程度地减少细胞炎症反应，同时增强生物相容性。
• Covalent attachment of specific binding members to a solid phase with
  申请人：Abbott Laboratories

  公开号：US05399501A1

  公开（公告）日：1995-03-21

  A specific binding member such as an antigen or antibody is immobilized by covalent attachment to a solid phase such as a latex microparticle. The solid phase is reacted with a heterobifunctional or homobifunctional coupling agent to form a complex that is then reacted with a dithiol compound to form a thiolated solid phase. A specific binding member is reacted with the coupling agent to form a complex which is then reacted with the thiolated solid phase to link the specific binding member to the solid phase through thioethers. Alternatively, the dithiol compound may be reacted with the specific binding member/coupling agent complex to form a thiolated complex that is reacted with the solid phase/coupling agent complex. The coupling agent may contain a spacer. In another embodiment, the solid phase is reacted with a disulfide compound to form a complex and the complex is reacted with a reductant to form a thiolated solid phase which is reacted with a specific binding member/coupling agent complex. The immobilized specific binding member can be used in diagnostic binding assays, and it has increased sensitivity, specificity and stability, while requiring the use of less specific binding member.

  一种特定的结合成员，如抗原或抗体，通过共价结合到固相上，如乳胶微粒。固相与杂二功能或同二功能偶联剂反应形成复合物，然后与二硫化合物反应形成硫化固相。特定的结合成员与偶联剂反应形成复合物，然后与硫化固相反应，通过硫醚键将特定的结合成员与固相链接。或者，二硫化合物可以与特定的结合成员/偶联剂复合物反应形成硫化复合物，然后与固相/偶联剂复合物反应。偶联剂可以包含一个间隔物。在另一种实施方式中，固相与二硫化合物反应形成复合物，然后与还原剂反应形成硫化固相，然后与特定的结合成员/偶联剂复合物反应。固定的特定结合成员可以用于诊断结合分析中，具有增加的灵敏度，特异性和稳定性，同时需要使用更少的特定结合成员。
• Method for selective targeting of apoptotic cells and small molecule ligands used thereof
  申请人：Ziv Ilan

  公开号：US20060160901A1

  公开（公告）日：2006-07-20

  The invention provides novel methods for selective targeting of chemical compounds to cells undergoing a death process, in particular apoptosis, and to platelets undergoing activation during blood coagulation. The invention further provides compounds to be used in said methods for medical practice, for diagnostic and therapeutic purposes.

  本发明提供了一种新颖的方法，用于选择性地将化学化合物靶向于正在经历死亡过程的细胞，特别是凋亡过程，以及在血液凝固期间激活的血小板。本发明还提供了用于上述方法的化合物，用于医疗实践、诊断和治疗目的。
• Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions
  申请人：Shafer A. Jules

  公开号：US20070149559A1

  公开（公告）日：2007-06-28

  The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors.

  本发明涉及从某些组合物中去除Michael受体的过程，其中所述组合物经过含硫醇化合物的处理，以足够的条件去除Michael受体和所得的硫醇-Michael加合物。本发明的某些实施例使得可以量化和/或去除Michael受体和/或Michael受体前体。